Home Healthcare Biotechnology RNA Therapeutics Market

RNA Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (mRNA Therapeutics, RNA interference (RNAi), Antisense oligonucleotides, Others), By Application (Oncology, Infectious Diseases, Genetic Diseases, Ophthalmology, Cardiovascular Diseases, Others), By End User (Hospitals & Clinics, Research Institutes, Others) and By Country (U.S., Canada) Forecasts, 2026-2034

Last Updated: July 09, 2026 | Author: Dhanashri B | Format: | Report Code: SR7208DR | Pages: 145
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. RNA Therapeutics Market, By Therapy Type 2022-2034 (USD MILLION/ Units)
    1. mRNA Therapeutics
    2. RNA interference (RNAi)
    3. Antisense oligonucleotides
    4. Others
  2. RNA Therapeutics Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Oncology
    2. Infectious Diseases
    3. Genetic Diseases
    4. Ophthalmology
    5. Cardiovascular Diseases
    6. Others
  3. RNA Therapeutics Market, By End User 2022-2034 (USD MILLION/ Units)
    1. Hospitals & Clinics
    2. Research Institutes
    3. Others
  4. Regional RNA Therapeutics Market
    1. North America
      1. North America RNA Therapeutics Market By Therapy Type 2022-2034 (USD MILLION/ Units)
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
      2. North America RNA Therapeutics Market By Application 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Infectious Diseases
        3. Genetic Diseases
        4. Ophthalmology
        5. Cardiovascular Diseases
        6. Others
      3. North America RNA Therapeutics Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research Institutes
        3. Others
      4. U.S.
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      5. Canada
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
    2. Europe
      1. Europe RNA Therapeutics Market By Therapy Type 2022-2034 (USD MILLION/ Units)
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
      2. Europe RNA Therapeutics Market By Application 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Infectious Diseases
        3. Genetic Diseases
        4. Ophthalmology
        5. Cardiovascular Diseases
        6. Others
      3. Europe RNA Therapeutics Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research Institutes
        3. Others
      4. U.K.
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      5. Germany
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      6. France
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      7. Spain
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      8. Italy
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      9. Russia
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      10. Nordic
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      11. Benelux
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      12. Rest of Europe
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
    3. APAC
      1. APAC RNA Therapeutics Market By Therapy Type 2022-2034 (USD MILLION/ Units)
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
      2. APAC RNA Therapeutics Market By Application 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Infectious Diseases
        3. Genetic Diseases
        4. Ophthalmology
        5. Cardiovascular Diseases
        6. Others
      3. APAC RNA Therapeutics Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research Institutes
        3. Others
      4. China
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      5. Korea
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      6. Japan
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      7. India
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      8. Australia
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      9. Taiwan
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      10. South East Asia
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      11. Rest of Asia-Pacific
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
    4. Middle East and Africa
      1. Middle East and Africa RNA Therapeutics Market By Therapy Type 2022-2034 (USD MILLION/ Units)
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
      2. Middle East and Africa RNA Therapeutics Market By Application 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Infectious Diseases
        3. Genetic Diseases
        4. Ophthalmology
        5. Cardiovascular Diseases
        6. Others
      3. Middle East and Africa RNA Therapeutics Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research Institutes
        3. Others
      4. UAE
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      5. Turkey
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      6. Saudi Arabia
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      7. South Africa
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      8. Egypt
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      9. Nigeria
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      10. Rest of MEA
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
    5. LATAM
      1. LATAM RNA Therapeutics Market By Therapy Type 2022-2034 (USD MILLION/ Units)
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
      2. LATAM RNA Therapeutics Market By Application 2022-2034 (USD MILLION/ Units)
        1. Oncology
        2. Infectious Diseases
        3. Genetic Diseases
        4. Ophthalmology
        5. Cardiovascular Diseases
        6. Others
      3. LATAM RNA Therapeutics Market By End User 2022-2034 (USD MILLION/ Units)
        1. Hospitals & Clinics
        2. Research Institutes
        3. Others
      4. Brazil
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      5. Mexico
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      6. Argentina
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      7. Chile
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      8. Colombia
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
      9. Rest of LATAM
        1. mRNA Therapeutics
        2. RNA interference (RNAi)
        3. Antisense oligonucleotides
        4. Others
        5. Oncology
        6. Infectious Diseases
        7. Genetic Diseases
        8. Ophthalmology
        9. Cardiovascular Diseases
        10. Others
        11. Hospitals & Clinics
        12. Research Institutes
        13. Others
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.